16.10.2012 - The European Commission gives €6m to a research consortium tackling a severe immune system disorder. „FIGHT HLH“ is led by Swiss Novimmune.
The European Commission wants to dismantle a malicious disease. By spending €6m of FP7 money for research into hemophagocytic lymphohistiocytosis (HLH), it wants to advance knowledge about possible treatment options about this orphan disease. The awardee is a consortium of institutions named FIGHT HLH. Among the institutions are Hospitals in Florence and Rome and Lonza Biologics plc. The consortium leader, however, is based in Switzerland. Novimmune SA from Geneva is the originator of the treatment option in question: NI-0501. This fully human monoclonal antibody is a potent inhibitor of the cytokine IFNγ, Cristina de Min, the company’s Chief Medical Officer, stresses the aim of the collaboration: „The programme is designed to give a clear readout on the ability of the drug to affect disease course.“ Novimmune CEO Jack Barbut adds that he is „delighted to have been selected by the European Commission for such a prestigious grant.“
HLH is caused by an impairment of cytotoxic T cell function that triggers an anomalous activation of the immune system. This activation stems mainly from an dramatic increase in IFNγ levels. NI-0501 targets IFNγ. Novimmune tested the drug in Phase I clinical trials successfully for safety and also demonstrated in animal studies that clearing excess IFNγ with the antibody reverses organ pathology and re-establishes key clinical parameters.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more